Evidence Grade E — Very limited evidence. 0 published studies. 0 registered clinical trials.
Medically reviewed by a licensed medical professional
SNAP-8 is an eight-amino-acid extension of Argireline, developed as a more potent version for cosmetic wrinkle reduction. At 1,075 Da, it is even larger than Argireline and faces greater challenges penetrating intact skin to reach its target. It faces a fundamental paradox: increased laboratory potency is offset by decreased ability to get through the skin. It has no pharmaceutical approval.
SNAP-8 is also known by these brand and alternate names:
No published studies found on PubMed.
SNAP-8 has no pharmaceutical authorisation. It is used as a cosmetic ingredient. An industry-sponsored open-label study (17 subjects) reported wrinkle reduction, with a maximum individual result of 63% — though this was a single-subject maximum, not a study average.
SNAP-8 illustrates a recurring challenge with cosmetic peptides: increased potency in laboratory assays does not address the fundamental question of whether the molecule can penetrate skin in sufficient quantities to reach its target. It is a topical cosmetic ingredient.
Research suggests SNAP-8 works through the same SNARE complex inhibition mechanism as Argireline but with approximately twice the potency in laboratory assays. However, its larger molecular size (1,075 Da versus 889 Da for Argireline) makes skin penetration to the target neuromuscular junctions even less likely than for its predecessor.
Research consists of a single manufacturer study (17 subjects, open-label design). The claimed 63% wrinkle reduction was a single-subject maximum, not a study average. Claimed superiority over Argireline is based on historical comparison rather than head-to-head testing. At 1,075 Da, SNAP-8 substantially exceeds the generally accepted 500 Da skin penetration threshold — even more so than Argireline (889 Da). No independent peer-reviewed clinical trials exist. It is a topical cosmetic ingredient.
PeptideTrace tracks 0 registered clinical trials for SNAP-8 sourced from ClinicalTrials.gov.
No trials registered on ClinicalTrials.gov for this compound.
SNAP-8 (Acetyl Octapeptide-3) is an 8-amino acid synthetic peptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2, essentially Argireline extended by two amino acids (Ala-Asp). Its molecular weight is 1,075.16 Da (CAS 868844-74-0). Developed by Lipotec (Lubrizol) as a next-generation SNARE inhibitor, SNAP-8 was designed to provide enhanced potency over its predecessor Argireline.
Research suggests SNAP-8 inhibits SNARE complex assembly through the same mechanism as Argireline but with approximately 2-fold greater potency: IC50 of 55 microM versus 110 microM for Argireline. The extended Ala-Asp sequence provides additional binding contacts with the SNARE complex components. Like Argireline, SNAP-8 competes with native SNAP-25 for SNARE complex formation, reducing vesicle fusion and acetylcholine release.
Lipotec conducted an open-label study (N=17, 28 days) reporting a maximum individual wrinkle reduction of 63.18%, with a mean of approximately 35% versus Argireline's historical mean of 27.05%. Independent research reports 10-30% wrinkle reduction with SNAP-8 formulations. However, the 63% claim is a single-subject maximum, not a study average, and the comparison uses historical cohort data rather than head-to-head testing. INCIDecoder's assessment notes weaker evidence compared to Argireline.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 13 vendor listings
View pricing data across vendors and countries for SNAP-8
GHK has no pharmaceutical authorisation. Small cosmetic studies of the copper-complexed form (GHK-Cu) have reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable use have been completed. As with GHK-Cu (#85), the cosmetic evidence base for topical use should be distinguished from claims about injectable use. Gene expression profiling studies have reported broad effects, but observational genomic changes do not constitute evidence of therapeutic efficacy. This entry overlaps substantially with GHK-Cu (#85).
GHK-Cu has no pharmaceutical authorisation from any regulatory agency. It is widely available as a cosmetic ingredient in over-the-counter skincare products, where it is marketed for skin conditioning. A small study comparing GHK-Cu cream to vitamin C and retinoic acid creams reported improvements in skin appearance measures. No pharmaceutical clinical trials for injectable GHK-Cu have been completed. The compound's cosmetic use (topical, in formulated skincare products) should be clearly distinguished from its unregulated availability as an injectable research compound. These represent fundamentally different risk profiles.
Argireline has no pharmaceutical authorisation. It is widely available as a cosmetic ingredient in over-the-counter skincare products. Small industry-sponsored studies have reported wrinkle depth reductions of 17–30% with topical application. The key scientific question is whether sufficient peptide penetrates intact skin to reach neuromuscular junctions and produce a meaningful effect. The molecule's size exceeds the conventional limit for transdermal absorption. Argireline's cosmetic use in formulated skincare products represents a fundamentally different risk profile from injectable use.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
